

ABSTRACT

INS
A2/

This invention provides a novel immunotolerance inducer which is effective in inducing immunological tolerance without involving any remarkable invasive procedure, thus ensuring the maintenance of a transplanted organ without administration of an immunosuppressant drug. This immunotolerance inducer is either a dual-system inducer comprising a first pharmaceutical composition for portal administration which comprises an effective amount of a tolerogen containing hematopoietic stem cells, hematopoietic progenitor cells, mature lymphocytes or a mixture thereof as the active component and a second pharmaceutical composition for intravenous administration which comprises an effective amount of the above-mentioned tolerogen as the active component or a single-system immunotolerance inducer which comprises an effective amount of a tolerogen containing hematopoietic stem cells, hematopoietic progenitor cells or a mixture thereof as an active component, said single-system immunotolerance inducer being administered in association with radiation.

662060-62508E60